They found that chronic treatment with the non-selective β-agonist isoprenaline promoted lymphoma development and significantly suppressed the proliferation, interferon gamma (IFNγ) production, and cytolytic killing capacity of antigen-specific CD8+ T cells. This evidence concerns the gene CD8A and lymphoma.